TP53 and neoplasm: RG7388 exhibited more than 100-fold selectivity over cell lines with mutated p53, activated the p53 pathway, promoted tumor regression at 25 mg/kg with daily doses in SJSA-1 mice xenograft [116,117] and is currently in clinical trials.